{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "PARK2",
        "Protein_Change": {
          "ref": "L",
          "alt": "R",
          "position": "Not Specified"
        },
        "variant_string_id": "PARK2 L-R"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Autosomal recessive juvenile parkinsonism (AR–JP) is characterized by selective dopaminergic neural cell death and the absence of the Lewy body. Mutations of PARK2 cause AR–JP. Parkin is involved in protein degradation as a ubiquitin-protein ligase collaborating with the ubiquitin-conjugating enzyme UbcH7.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism – selective dopaminergic neuron death in AR-JP, links it to PARK2 mutations, and establishes the role of parkin in protein degradation via the ubiquitin-protein ligase pathway.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "parkin is involved in protein degradation as a ubiquitin-protein ligase collaborating with the ubiquitin-conjugating enzyme UbcH7, and that mutant parkins from AR–JP patients show loss of the ubiquitin-protein ligase activity.",
          "judgment": "Yes",
          "reasoning": "The assays described (measuring ubiquitin-protein ligase activity) directly reflect the established role of parkin in protein degradation and are applicable to understanding the pathogenesis of AR-JP.",
          "next_step_or_outcome": "Proceed to Step 1a"
        },
        {
          "step_name": "Step 1a: Basic Controls and Replicates",
          "extracted_paper_info": "The paper doesn't explicitly state the use of 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls nor explicitly states the use of replicates.",
          "judgment": "No",
          "reasoning": "The paper does not provide explicit details on controls or replicates, therefore the standard proceed to 1b"
        },
        {
          "step_name": "Step 1b: Accepted/Validated Assay (if basic controls/replicates were insufficient in 1a)",
          "extracted_paper_info": "N/A",
          "judgment": "No",
          "reasoning": "Since the study did not detail controls and replicates, it does not have the validation required.",
          "next_step_or_outcome": "Functional evidence strength: Max PS3_supporting / Max BS3_supporting."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "Max PS3_supporting"
      },
      "overall_conclusion": "The paper establishes that mutations in PARK2 lead to a loss of ubiquitin-protein ligase activity in parkin, contributing to AR-JP. However, lack of documented use of basic controls or replicates diminish the evidentiary strength."
    }
  ]
}